Want to see IN:NGLFINE full AI Analyst Report?
NGLFINE Stock Chart & Stats
₹1427.00
₹2.30(0.13%)
At close: 4:00 PM EST
₹1427.00
₹2.30(0.13%)
Day’s Range― - ―
52-Week Range₹1,142.70 - ₹3,227.90
Previous CloseN/A
Volume1.22K
Average Volume (3M)156.00
Market Cap
₹19.14B
Enterprise Value₹19.14B
Total Cash (Recent Filing)₹637.29M
Total Debt (Recent Filing)₹882.03M
Price to Earnings (P/E)40.0
Beta0.98
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.13%
Share Statistics
EPS (TTM)33.49
Shares Outstanding6,178,024
10 Day Avg. Volume192
30 Day Avg. Volume156
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.86
Price to Sales (P/S)2.54
P/FCF Ratio-25.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA clear revenue re-acceleration in 2026 (+22.6%) indicates recovering end-market demand and stronger top-line momentum. Sustained revenue growth over several quarters would underpin capacity utilization, pricing leverage and justify reinvestment to scale higher-margin segments.
Profitability RecoveryNet margin improvement to ~9.6% alongside revenue growth reflects operational recovery and some restoration of pricing or mix. If sustained, improved margins translate to stronger internal capital generation and higher returns on reinvested capital over the medium term.
Manageable Leverage And Equity GrowthDebt levels remain moderate while equity has expanded, preserving borrowing capacity. A balanced capital structure supports funding for capex or working capital needs without immediate refinancing pressure, allowing strategic investments to support sustainable growth.
Bears Say
Gross-margin CompressionA sharp decline in gross margin from ~50% to ~35% is a structural red flag: it erodes the profit base, limits operating-leverage benefits from revenue growth, and makes earnings more sensitive to cost or pricing shocks unless the company reverses input cost trends or shifts mix to higher-margin products.
Weak Cash ConversionPersistent negative free cash flow and low cash conversion mean reported profits aren’t translating into spendable cash. That constrains self-funded growth, raises dependency on external financing for capex or working capital, and increases vulnerability if credit conditions tighten.
Rising Indebtedness TrendAlthough current leverage is moderate, the clear upward trend in debt-to-equity over successive years signals growing financial commitments. Continued increases could pressure interest coverage, reduce flexibility for opportunistic investments, and raise refinancing risk if profits falter.
NGL Fine-Chem Ltd. News
NGLFINE FAQ
What was NGL Fine-Chem Ltd.’s price range in the past 12 months?
NGL Fine-Chem Ltd. lowest stock price was ₹1142.70 and its highest was ₹3227.90 in the past 12 months.
What is NGL Fine-Chem Ltd.’s market cap?
NGL Fine-Chem Ltd.’s market cap is ₹19.14B.
When is NGL Fine-Chem Ltd.’s upcoming earnings report date?
NGL Fine-Chem Ltd.’s upcoming earnings report date is Jul 31, 2026 which is in 30 days.
How were NGL Fine-Chem Ltd.’s earnings last quarter?
NGL Fine-Chem Ltd. released its earnings results on May 21, 2026. The company reported ₹21.83 earnings per share for the quarter, beating the consensus estimate of N/A by ₹21.83.
Is NGL Fine-Chem Ltd. overvalued?
According to Wall Street analysts NGL Fine-Chem Ltd.’s price is currently Overvalued.
Does NGL Fine-Chem Ltd. pay dividends?
NGL Fine-Chem Ltd. pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.13%. See more information on NGL Fine-Chem Ltd. dividends here
What is NGL Fine-Chem Ltd.’s EPS estimate?
NGL Fine-Chem Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NGL Fine-Chem Ltd. have?
NGL Fine-Chem Ltd. has 6,178,024 shares outstanding.
What happened to NGL Fine-Chem Ltd.’s price movement after its last earnings report?
NGL Fine-Chem Ltd. reported an EPS of ₹21.83 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.702%.
Which hedge fund is a major shareholder of NGL Fine-Chem Ltd.?
Currently, no hedge funds are holding shares in IN:NGLFINE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NGL Fine-Chem Ltd.
Headquartered in Mumbai, India, and established in 1981, NGL Fine-Chem Limited operates as a worldwide producer and distributor of pharmaceutical ingredients and intermediates for both veterinary and human health sectors. The company's comprehensive portfolio of active pharmaceutical ingredients (APIs) for animal applications features substances like diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin. For human therapeutic use, they supply APIs including nitazoxanide, atovaquone, and ranolazine. Furthermore, NGL Fine-Chem manufactures various intermediate compounds and offers completed pharmaceutical formulations in both granule and tablet formats.
Technical Analysis
Gland Pharma Ltd.
―
Kopran Limited
―
Marksans Pharma Limited
―
SMS Pharmaceuticals Limited
―
Senores Pharmaceuticals Ltd.
―